Company's NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms ...

Market OverviewBreast cancer remains one of the most prevalent forms of cancer worldwide, affecting millions of individuals ...

Real-time index price for Nasdaq Biotechnology Index (NBI), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Baron Funds, an investment management company, released its “Baron Discovery Fund” first quarter 2025 investor letter. A copy ...

Luton, Bedfordshire, United Kingdom, May 20, 2025 (GLOBE NEWSWIRE) -- The micro-volume spectrophotometer is a specialized analytical instrument designed to measure the concentration and purity of ...

Pfizer will pay China’s 3SBio $1.25 billion upfront to gain access to a cancer therapy that could rival Akeso and Summit’s closely watched immunotherapy ivonescimab.

BURLINGAME, CA, UNITED STATES, May 20, 2025 /EINPresswire.com/ -- Biotechnology Market is estimated to be valued at USD 1,034.63 Bn in 2025 and is expected to reach USD 2,330.47 Bn in 2032, exhibiting ...

Indian drugmaker Zydus Lifesciences reported a higher adjusted fourth-quarter profit on Tuesday, driven by new drug launches in the U.S., its biggest market.

Deeptech spans AI, quantum computing, biotech, and more, impacting sectors from healthcare to manufacturing. To foster growth, the government should consider a sovereign investment company, thematic ...

Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug. Shares were up ...

Real-time index price for Nasdaq Biotechnology Index (NBI), along with buy or sell indicators, analysis, charts, historical performance, news and more ...